Key Insights

Highlights

Treatment Research

1 treatments under study, led by Ecopipam

Related Conditions

Often studied with 8 related conditions

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

50.0%

1 terminated out of 2 trials

Success Rate

0.0%

-86.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

0

Data Visualizations

Phase Distribution

1Total
Phase 2/3 (1)

Trial Status

Terminated1
Unknown1

Clinical Trials (2)

Showing 2 of 2 trials
NCT00001308TerminatedPrimary

Central Mechanisms in Speech Motor Control Studied With H215O PET

NCT02909088Phase 2/3Unknown

Efficacy and Tolerability of Ecopipam in Adults With Childhood Onset Fluency Disorder (Stuttering).

Showing all 2 trials

Research Network

Common Treatments

  • Ecopipam1

Active Sponsors

  • National Institute on Deafness and Other Communication Disorders (NIDCD)1
  • University of California Riverisde School of Medicine1
  • Gerald Maguire, MD1

Top Investigators

Related Conditions

  • Stuttering Adult1
  • Voice Disorder1
  • Speech Disorders1
  • Language Disorders1
  • Stuttering1

Activity Timeline